{"id":"plb1001","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Gastrointestinal toxicity"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL4650443","moleculeType":"Small molecule","molecularWeight":"424.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PLB1001 is designed to inhibit key signaling pathways that drive tumor growth. The drug works by blocking kinase activity in cancer cells, disrupting their ability to proliferate and survive. It is being developed primarily for hematologic malignancies and solid tumors.","oneSentence":"PLB1001 is a small-molecule inhibitor that targets specific kinases involved in cancer cell proliferation and survival.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:29:12.289Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Other hematologic malignancies"}]},"trialDetails":[{"nctId":"NCT06105619","phase":"PHASE2, PHASE3","title":"A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2018-10-08","conditions":"Glioblastoma","enrollment":84},{"nctId":"NCT05989542","phase":"PHASE3","title":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","status":"RECRUITING","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2023-10-16","conditions":"Non-small Cell Lung Cancer","enrollment":136},{"nctId":"NCT03175224","phase":"PHASE2","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","status":"RECRUITING","sponsor":"Apollomics Inc.","startDate":"2017-09-27","conditions":"Solid Tumors, Advanced Cancer, Renal Cancer","enrollment":497},{"nctId":"NCT06343064","phase":"PHASE1, PHASE2","title":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","status":"RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2023-06-13","conditions":"Non-Small-Cell Lung Cancer","enrollment":156},{"nctId":"NCT06970782","phase":"PHASE3","title":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure","status":"NOT_YET_RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2025-05-15","conditions":"Non-Small-Cell Lung Cancer","enrollment":278},{"nctId":"NCT06574347","phase":"PHASE2","title":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","status":"RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2024-08-07","conditions":"Non-Small-Cell Lung Cancer","enrollment":120},{"nctId":"NCT06827145","phase":"PHASE2","title":"Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, China","startDate":"2024-10-14","conditions":"Non-Small-Cell Lung Cancer","enrollment":30},{"nctId":"NCT04258033","phase":"PHASE2","title":"A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2020-01-17","conditions":"Non-small Cell Lung Cancer","enrollment":145},{"nctId":"NCT05367388","phase":"PHASE1","title":"A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants","status":"UNKNOWN","sponsor":"Apollomics Inc.","startDate":"2022-05-20","conditions":"Bioequivalence","enrollment":48},{"nctId":"NCT02978261","phase":"PHASE1","title":"Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas","status":"COMPLETED","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2016-09","conditions":"Glioma","enrollment":18},{"nctId":"NCT02896231","phase":"PHASE1","title":"First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001","status":"COMPLETED","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2016-04","conditions":"Non-Small Cell Lung Cancer","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bozitinib","Vebreltinib"],"phase":"phase_3","status":"active","brandName":"PLB1001","genericName":"PLB1001","companyName":"Beijing Pearl Biotechnology Limited Liability Company","companyId":"beijing-pearl-biotechnology-limited-liability-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PLB1001 is a small-molecule inhibitor that targets specific kinases involved in cancer cell proliferation and survival. Used for Acute myeloid leukemia (AML), Other hematologic malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}